BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Files An 8-K Submission of Matters to a Vote of Security Holders

BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders

Story continues below

On March 19, 2018, Bioanalytical Systems Inc. (the “Company”) held its annual meeting of shareholders at its corporate offices located at 2701 Kent Avenue, West Lafayette, IN 47906. A total of 5,485,909 shares of the Company’s common stock outstanding and entitled to vote were present at the meeting in person or by proxy. The following is a summary of the matters voted on at the meeting.

a.) One Class III member of the Board of Directors was elected to serve a three-year term ending in 2021 with the following votes cast:
Nominee For Withheld Broker Non- Vote
Gregory C. Davis, Ph.D. 2,982,200 518,716 1,984,993
b.) The appointment of RSM US LLP as our independent registered public accountants for fiscal 2018 was ratified by the following shareholder vote:
Vote Type Voted
For 5,441,411
Against 12,562
Abstain 31,936
c.) The proposal to approve the amendment and restatement of the 2008 Stock Option Plan in the form of the Bioanalytical Systems, Inc. 2018 Equity Incentive Plan passed with the following votes cast:
Vote Type Voted
For 2,930,967
Against 534,833
Abstain 35,116


Bioanalytical Systems, Inc. (BASi) is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The Company operates through two segments: contract research services and research products. Its contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies. Its research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Its Culex family of robotic automated dose delivery, blood and other biofluids sampling and physiological parameters measurement systems enable researchers to determine pharmacokinetic/pharmacodynamic (PK/PD) profiles of drugs in large and small animal models. The Company’s bioanalytical services group supports research, preclinical and clinical programs.

An ad to help with our costs